Thrombolytic therapy for pulmonary embolism

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Hao, Qiukui ^a   Dong, Bi Rong ^a   Yue, Jirong ^a   Wu, Taixiang ^a   Liu, Guan J ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; PLASMINOGEN;

ARTERIAL OXYGEN TENSION; BLEEDING; BLOOD CLOTTING; CARDIAC INDEX; CAUSE OF DEATH; CLINICAL OUTCOME; COMPARATIVE STUDY; DISEASE SEVERITY; FIBRINOLYTIC THERAPY; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE SIZE; HEMATOLOGICAL PARAMETERS; HUMAN; INFERIOR CAVA VEIN; LENGTH OF STAY; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG HEMODYNAMICS; LUNG RESISTANCE; LUNG SCINTISCANNING; MEAN ARTERIAL PRESSURE; META ANALYSIS; PATIENT MONITORING; PRESSURE GRADIENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRICUSPID VALVE REGURGITATION; VEIN DIAMETER; VENOUS OXYGEN TENSION; ADVERSE EFFECTS; MORTALITY; PROCEDURES; PULMONARY EMBOLISM;

FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOLYTIC THERAPY;

EID: 84961230016     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004437.pub4     Document Type: Review

References (113)

1. Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi LG, Enea I, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thrombosis Research 2010;125(3):e82-6.
2. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al. PAIMS2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology 1992;20(3):520-6.
3. Dotter CT, Seamon AJ, Rosch J, Porter J. Streptokinase and heparin in the treatment of major pulmonary embolism: a randomised comparison. Vascular Surgery 1979;13(1):42-52.
4. Fasullo S, Scalzo S, Maringhini G, Ganci F, Cannizzaro S, Basile I, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. American Journal of the Medical Sciences 2011;341(1):33-9.
5. Goldhaber SZ, Haire WD, Fekdstein ML, Miller M, Toltzis R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. The Lancet 1993;341(8844):507-11.
6. Jerjes-Sánchez C, Ramírez-Rivera A, De Lourdes-García M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. Journal of Thrombosis and Thrombolysis 1995;2(3):227-9.
7. Kline J, Hernandez J, Kabrhel C, Courtney DM, Jones AE, Nordenholtz K, et al. Randomized trial of tenecteplase or placebo with low molecular weight heparin for acute submassive pulmonary embolism: Assessment of patient-oriented cardiopulmonary outcomes at three months. Journal of the American College of Cardiology 2013;61(10 Suppl 1):E2074.
8. Kline JA, Hernandez J, Hogg MM, Jones AE, Courtney DM, Kabrhel C, et al. Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Emergency Medicine Australasia 2013;25(6):515-26. [DOI: 10.1111/1742-6723.12159]
9. Kline JA, Hernandez J, Kabrhel C, Courtney DM, Nordenholtz KE, Diercks DB, et al. Randomized trial of tenecteplase or placebo with low molecular weight heparin for acute submassive pulmonary embolism: assessment of patient-oriented cardiopulmonary outcomes at three months. Academic Emergency Medicine 2013;20(5 Suppl 1):S7.
10. Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. Journal of Thrombosis and Haemostasis 2014;12(4):459-68. [: NCT00680628]
11. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. New England Journal of Medicine 2002;347(15):1143-50.
12. Kucher N, Boekstegers P, Muller O, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014;129(4):479-86. [: NCT01166997]
13. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98(6):1473-9.
14. Arnesen BLH, Eie H, Hol R. A prospective study of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Medica Scandinavica Supplement 1978; Vol. 621:15.
15. Ly B, Arneson H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Medica Scandinavica 1978;203(6):465-70.
16. Giuntini C, Marini C, Di Ricco G, Palla R, Giacomelli V, Rindi M. A controlled clinical trial on the effect of heparin infusion and two regimens of urokinase in acute pulmonary embolism. Giornale Italiano di Cardiologia 1984;14(Suppl 1):26-9.
17. Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988;54(3):162-73.
18. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. New England Journal of Medicine 2014;370(15):1402-11. [: NCT00639743]
19. NCT00639743. PEITHO Pulmonary Embolism Thrombolysis Study. http://clinicaltrials.gov/ct2/show/NCT00639743?term=thrombolysis&rank=14 (accessed April 2009).
20. PEITHO Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. American Heart Journal 2012; Vol. 163, issue 1:33-38. [: NCT00639743]
21. PIOPED Investigation Committee. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED investigators. Chest 1990;97(3):528-33.
22. SharifiM, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the "mOPETT" Trial). American Journal of Cardiology 2013;111(2):273-7.
23. Taherkhani M, Taherkhani A, Hashemi SR, Langroodi TF, Sadeghi R, Beyranvand M. Thrombolytic-plus-anticoagulant therapy versus anticoagulant-alone therapy in submassive pulmonary thromboembolism (TVASPE study): a randomized clinical trial. Journal of Tehran University Heart Center 2014;9(3):104-8.
24. Tibbutt DA, Davies JA, Anderson JA, Fletcher EW, Hamill J, Thomas ML, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. British Medical Journal 1974;1(904):343-7.
25. Sasahara AA, Hyers TM, Cole CM, Ederer F, Murray JA, Wenger NK, et al. The urokinase pulmonary embolism trial. Circulation 1973;47(2 Suppl):7-21.
26. Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. New England Journal of Medicine 1980;303(15):842-5.
27. UPET. Urokinase pulmonary embolism trial. Phase 1 results: a co-operative study. JAMA 1970;214(12):2163-71.
28. Abdelsamad AA, El-Morsi AS, Mansour AE. Efficacy and safety of high dose versus low dose streptokinase for treatment of submassive pulmonary embolism. Egyptian Heart Journal 2011;63:67-72.
29. Agnelli G, Iorio A, Parise P, Goldhaber SZ, Levine MN. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. Blood Coagulation and Fibrinolysis 1997;8(4):216-22.
30. Bell WR, Simon TL, Stengle JM, Sherry S. The urokinase-streptokinase pulmonary embolism trial (phase II) results. Circulation 1974;50(6):1070-1.
31. Bell WR. Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national co-operative study. Thrombosis and Haemostasis 1976;35(1):57-69.
32. Bell WR. Thrombolytic therapy: differences between streptokinase and urokinase. Vascular Surgery 1977;11:378-83.
33. Bhardwaj S, Krishna CK, Mukherjee N, Sambi RS, Aggarwal KK, Kapoor N, et al. Treatment of massive pulmonary embolism by tenecteplase. Indian Heart Journal 2010 Sep;62(5):454-5.
34. Charbonnier B, Raynaud P, Griguier P, Brochier M. Potentializing effects of a defibrillating agent on therapeutic thrombolysis in pulmonary embolism [Effets potentialisateurs d'un agent defibrinant sur la thrombolyse therapeutique dans l'embolie pulmonaire]. Archives des Maladies du Coeur et des Vaisseaux 1984; Vol. 77:1426.
35. Chen Z. Evaluation of effect of rt-PA therapy and different dose in acute pulmonary embolism [Abstract]. American Thoracic Society 2009 International Conference; 2009 May 15-20; San Diego. American Journal of Respiratory and Critical Care Medicine. 2009; Vol. 179 (Meeting Abstracts):A3294.
36. Comerota AJ. The ATTRACT trial: rationale for early intervention for iliofemoral DVT. Perspectives in Vascular Surgery and Endovascular Therapy 2009;21:221-4.
37. De Takats G. The urokinase pulmonary embolism trial. American Journal of Surgery 1973;126(3):311-3.
38. Erkan L, Findik S, Atici AG, Uzun O. Thrombolytic therapy in massive pulmonary thromboembolism. European Respiratory Journal 2002; Vol. 20:237s.
39. Francois G, Charbonnier B, Raynaud P, Garnier LF, Griguer P, Brochier M. Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. 67 cases [Traitemente de l'embolie pulmonaire aigue par urokinase comparee a l'association plasminogene-urokinase. A propos de 67 cas]. Archives des Maladies du Coeur et des Vaisseaux 1986;79(4):435-42.
40. Goldhaber SZ. TPA versus urokinase in acute pulmonary embolism: results of a randomized controlled trial. Vasa - Supplementum 1989;27:292-4.
41. Goldhaber SZ. Tissue plasminogen activator in acute pulmonary embolism. Chest 1989;95(5 Suppl):282S-9S.
42. Goldhaber SZ, Kessler CM, Heit JA, Elliot CG. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. Journal of the American College of Cardiology 1992;20(1):24-30.
43. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomised trial. Chest 1994;106(3):718-24.
44. IRCT201104245625N2. Comparative efficacy and complications of two-hour versus 24-hour regimen of streptokinase in acute pulmonary embolism In Tehran Heart Center. http://www.irct.ir/searchresult.php?id=5625&number=2 (accessed September 2015). [: IRCT201104245625N2]
45. Jin J, Ding WB, Yuan RF. Thrombolytic treatment of acute pulmonary thromboembolism: comparison between catheter-directed thrombolysis and venous thrombolysis. Journal of Interventional Radiology 2012;21:667-71.
46. Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. American Journal of Cardiology 1998;82(8):966-70.
47. Liu FY, Wang MQ, Duan F, Wang ZJ, Song P, Wang Y, et al. Management of acute massive with interventional techniques. Zhonghua Yi Xue Za Zhi 2012;92(19):1343-5.
48. Marder VJ, Donahoe JF, Bell WR, Cranley JJ, Kwaan HC, Sashara AA, et al. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism. Journal of Laboratory Clinical Medicine 1978;92(5):721-9.
49. Meneveau N, Schiele F, Vuillemenot A, Valette B, Grollier G, Bernard Y, et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. European Heart Journal 1997;18(7):1141-8.
50. Meneveau N, Schiele F, Metz D, Valette B, Attali P, Vuillemenot A, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. Journal of the American College of Cardiology 1998;31(5):1057-63.
51. Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al. Comparison of the effect of an intravenous infusion of urokinase or alteplase on total pulmonary resistance in acute massive pulmonary embolism. A European, multi-center, double-blind study [Vergleich der wirkung einer intravenosen infusion von urokinase oder alteplase auf den pulmonalen en gesamtwiderstand bei akuter massiver lungenembolie. Eine Europapaische multicenter-doppelblindestudie]. Intensivmedizin und Notfallmedizin 1992;29:339-47.
52. Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. Journal of the American College of Cardiology 1992;19(2):239-45.
53. Miller GAH, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. British Medical Journal 1971;763(2):681-4.
54. Muhl D, Furedi R, Gecse K, Ghosh S, Falusi B, Bogar L, et al. Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism. Blood Coagulation and Fibrinolysis 2007;18(7):661-7.
55. NCT00639743. Recombinant streptokinase versus urokinase in pulmonary embolism in China (RESUPEC). http://clinicaltrials.gov/ct2/show/NCT00639743 (accessed September 2015).
56. NCT01956955. Comparison of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in combination with thrombolytic treatment of acute massive pulmonary thromboembolism. https://clinicaltrials.gov/ct2/show/NCT01956955 (accessed September 2015).
57. Ohayon J, Colle JP, Tauzin-Fin P, Lorient-Roudaut MF, Besse P. Hemodynamic course during fibrinolysis in severe pulmonary embolism [Évolution hémodynamique au cours des fibrinolyses de l'embolie pulmonaire grave]. Archives des Maladies du Coeur et des Vaisseaux 1986;79(4):445-53.
58. Palla A, Pazzagli M, Manganelli D, De Nitto P, Marini C, Rossi G, et al. Resolution of pulmonary embolism: effect of therapy and putative age of emboli. Respiration 1997;64(1):50-3.
59. Pang BS, Wang C, Lu Y, Yang YH, Xing GH, Mao YL, et al. Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2007;87:3074-8.
60. Prandoni P, Zambon G, Scatigna M. Diagnostic approaches and results in the medical treatment of pulmonary thromboembolism [Aspetti diagnostici e risultati della terapia medica nella tromboembolia polmonare]. Minerva Medica 1985;76(38):1727-37.
61. Research Group on Urokinase and Pulmonary Embolism. Multicenter study of 2 urokinase protocols in severe pulmonary embolism [Étude multicentrique sur deux protoocles d'ukokinase dans l'embolie pulmonaire grave]. Archives des Maladies du Coeur et des Vaisseaux 1984;77(7):773-81.
62. Saponjski JD, Saponjski MD, Vukcevic VP. Massive pulmonary embolism and thrombolysis in the first week after major surgery. European Respiratory Journal 2002;20(Suppl 38):239s.
63. Sasahara AA, Bell WR, Simon TL, Stengle JM, Sherry S. The phase II. urokinase-streptokinase pulmonary embolism trial: a national cooperative study. Thrombosis et Diathesis Haemorrhagica 1975;33(3):464-76.
64. Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism. Vascular Medicine 2000;5(2):91-5.
65. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994;106(3):712-7.
66. Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. American Heart Journal 1999;138(7):39-44.
67. Tebbe U, Bramlage P, Graf A, Lechleitner P, Bode C, Riess FC, et al. Desmoteplase in acute massive pulmonary thromboembolism. Thrombosis and haemostasis 2009;101:557-62.
68. The UKEP Study Research Group. The UKEP Study: multicentre clinical trial on two local regimes of urokinase in massive pulmonary embolism. European Heart Journal 1987;8(1):2-10.
69. The urokinase pulmonary embolism trial study group. Urokinase streptokinase embolism trial. Phase 2 results. A co-operative study. Journal of the American Medical Association 1974;229:1606-13.
70. Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988;77(2):353-60.
71. Wang C. The clinical features of 516 patients with acute pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2006;86(31):2161-5.
72. Yang YH, Zhai ZG, Wang F, Xie WM, Wang C. Changes in deep venous thrombosis after thrombolytic anticoagulant therapies in acute pulmonary thromboembolism. Chinese Journal of Internal Medicine 2009;48:371-374.
73. Wang Y, Yang Y, Wu Y, Wang C. The echocardiographic changes of pre and after treatments of recombinant streptokinase and urokinase on pulmonary embolism [Abstract]. Respirology 2009;14:A137.
74. Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010;137:254-62.
75. Wang C, Zhai Z, Yang Y, Yuan Y, Cheng Z, Liang L, et al. Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial [Abstract]. Respiratory Research 2009;10:128.
76. Wu YQ, Tao LB, Lu C, Hu YH. An economic evaluation of low dose recombinant human tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2010;90:103-6.
77. Yang D, Zhao G, Wu H, Zhou H, Ji Y, Zhang Z. Comparison of local and systemic thrombolytic treatment for acute massive pulmonary embolism [Abstract]. European Respiratory Journal 2007;30:544s.
78. Yang Y, Wang Y, Ma Z, Qiu C, Wu H, Zhang X, et al. Efficacy and safety of two-hour regimen of recombinant streptokinase versus urokinase in massive and submassive pulmonary embolism [Abstract]. Respirology 2011;16:309.
79. Zhu L, Wang C, Yang Y, Wu Y, Zhai Z, Dai H, et al. Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism. Journal of Thrombosis and Thrombolysis 2008;26:251-6.
80. 2005-001070-27. Open, randomised, monosite pilot trial for comparison of thrombolytic efficacy of tenecteplase and alteplase in patients with acute pulmonary embolism. https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001070-27 (accessed January 2015).
81. NCT00680628. Randomized trial of tenecteplase to treat severe submassive pulmonary embolism. http://clinicaltrials.gov/ct2/show/NCT00680628?cond=pulmonary+embolism&rank=42 (accessed January 2015).
82. NCT01531829. Low dose Rt-PA for acute normotensive pulmonary embolism with RVD. http://www.clinicaltrials.gov/ct2/show/NCT01531829?term=pulmonary+embolism+and+thrombolysis&rank=5 (accessed January 2015).
83. Bottiger BW, Bohrer H, Bach A, Motsch J, Martin E. Bolus injection of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism. Resuscitation 1994;28(1):45-54.
84. Browse NL, James DC. Streptokinase and pulmonary embolism. The Lancet 1962;2:1039.
85. Cao Y, Zhao H, Gao W, Wang Y, Cao J. Systematic review and meta-analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism. Patient Preference and Adherence 2014;28(8):275-82.
86. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. Journal of the American Medical Association 2014;311(23):2414-21.
87. Chesterman CN, Biggs JC, Morgan J, Hickie JB. Streptokinase therapy in acute major pulmonary embolism. Medical Journal of Australia 1969;2(22):1096-100.
88. Condliffe R, Elliot CA, Hughes RJ, Hurdman J, Maclean RM, Sabroe I, et al. Management dilemmas in acute pulmonary embolism. Thorax 2014;69(2):174-80.
89. Genton E, Wolf P. Urokinase therapy in pulmonary thromboembolism. American Heart Journal 1968;76(5):628-37.
90. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GVRK, Dawley D, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. The Lancet 1988;2(8606):293-8.
91. Goldhaber SZ. Thrombolysis for pulmonary embolism. New England Journal of Medicine 2002;347(15):1131-2.
92. Jan Brozek, Andrew Oxman. GRADEpro Version 3.2 for Windows. Holger Schünemann, 2008.
93. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Wiley-Blackwell.
94. Hirsh J, McDonald IG, Hale GA, O'Sullivan EF, Jelinek VM. Comparison of the effects of streptokinase and heparin on the early rate of resolution of major pulmonary embolism. Canadian Medical Association Journal 1971;104(6):488-91.
95. Hyers TM, Stengle JM, Sherry S. Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1). Circulation 1970;42(6):979-80.
96. JaffMR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123(16):1788-830.
97. Konstantinides S, Geibel A, Kasper W. Submassive and massive pulmonary embolism: a target for thrombolytic therapy?. Thrombosis and Haemostasis 1999;82(Suppl 1):104-8.
98. Liu Y, Lu Y, Song J, Li D, Liu H, Yang J, et al. Recombinant tissue plasminogen activator for hemodynamically stable patients experiencing an acute pulmonary embolism: a meta-analysis. Thrombosis Research 2014;134(1):50-6.
99. Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. European Heart Journal 2014;36(10):605-14.
100. Meneveau N, Séronde MF, Blonde MC, Legalery P, Didier-Petit K, Briand F, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006;129(4):1043-50.
101. Nakamura S, Takano H, Kubota Y, Asai K, Shimizu W. Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta-analysis. Journal of Thrombosis and Haemostasis 2014;12(7):1086-95.
102. National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. http://www.nice.org.uk/guidance/cg144 2012 (accessed August 2015).
103. Perlroth DJ, Sanders GD, Gould MK. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Archives of Internal Medicine 2007;167(1):74-80.
104. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
105. Sasahara AA, Cannilla JE, Belko JS, Morse RL, Criss AJ. Urokinase therapy in clinical pulmonary embolism. A new thrombolytic agent. New England Journal of Medicine 1967;277(22):1168-73.
106. Sasahara AA, Hyers TM, Cole CM, Ederer F, Murray JA, Wenger NK, et al. The urokinase pulmonary embolism trial: a national co-operative study. Circulation 1973;47(2 Suppl):7-21.
107. Sautter RD, Emanuel RA, Fletcher FW, Wenzel FJ, Matson JI. Urokinase for the treatment of acute pulmonary thromboembolism. Journal of the American Medical Association 1967;202(3):215-8.
108. Tow DE, Wagner HN Jr, Holmes RA. Urokinase in pulmonary embolism. New England Journal of Medicine 1967;277(22):1161-7.
109. Vander Sande J, Bossaert L, Brochier M, Charbonnier B, Serradigmini A, Elias A, et al. Thrombolytic treatment of pulmonary embolism with APSAC. European Respiratory Journal 1988;1(8):721-5.
110. Yamasawa F, Okada Y, Asano K, Mori M, Fujita H, Hasegawa N, et al. The role of recombinant human tissue-type plasminogen activator in the treatment of acute pulmonary thromboembolism. Internal Medicine 1992;31(7):885-8.
111. Dong B, Pineo G, Mulrooney T. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD004437]
112. Dong BR, Yue J, Liu GJ, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004437.pub2]
113. Dong BR, Hao Q, Yue J, Wu T, Liu GJ. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD004437.pub3]